Stock Movers: Minimax, M3. DBS (Podcast)

Minimax extended its rally, jumping 18% after Southbound investors bought HK$2.7B ($344M) of shares on the first day of inclusion. M3 shares fell as much as 21% after 1Q profit missed expectations and pharma marketing growth slowed. In Singapore banking, DBS (Q2 profit up 42% to S$919M) and peers benefited from wealth management, with wealth fees at all-time highs and helped drive shares to record levels.

Analysis

The cleaner read-through is liquidity, not just fundamentals: cross-border inclusion can create a mechanically supportive bid that lasts days to a few weeks, but the durability depends on whether southbound participation broadens beyond the first-day novelty. That favors momentum traders and squeezes shorts, while leaving local peers exposed to relative underperformance if they do not get the same passive/flow tailwind.

The Singapore banks are the more interesting structural setup. Wealth-fee acceleration improves operating leverage and quality of earnings, which should support premium multiples even if net interest income normalizes; over 6-18 months, the market may start valuing them more like fee-rich wealth platforms than rate proxies. The second-order loser is anyone competing for affluent deposits and managed assets, because stronger franchises can defend pricing while still taking share.

M3 looks like a classic budget-cycle miss: pharma marketing softness tends to be delayed-cycle and sticky, so the risk is not one bad quarter but a 1-2 quarter revision cycle in adjacent healthcare info and commercial services names. Contrarian view: after a 20%+ gap-down, the market may already be discounting a protracted slowdown; if guidance holds and the issue is mix rather than structural demand loss, the downside can mean-revert quickly. Falsifier for the bearish case is an explicit reacceleration in pharma marketing growth or margin stabilization next print.

Key Decisions for Investors

• Buy pullbacks in Singapore bank proxies OVCHY / UOVEY / UILCY over the next 1-3 weeks; thesis is multiple expansion on fee-mix improvement, with risk defined by next-quarter wealth-fee growth or deposit beta deteriorating.
• Short MTHRY on any relief rally or via a 1-3 month put spread; target is a post-miss revision cycle, with the trade invalidated if management re-accelerates pharma marketing or restores guidance.
• Do not chase the inclusion-flow name after a two-day move; instead set a watchlist alert for southbound turnover staying elevated for 3-5 sessions. If flows fade quickly, treat the move as tactical and avoid momentum longs.
• Relative-value idea: long OVCHY/UOVEY vs. a broad Asia financials proxy if the market starts pricing lower-for-longer rates, because wealth fees can offset NII pressure better than plain-vanilla lenders.